Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PER2 | O15055 | 2/20 | 0.34 |
| ▸ | CRY2 | Q49AN0 | 2/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13216615 | 0.87 | RARA (0.35) | PER2CRY2OPRM1OPRD1OPRK1 | |
| SCHEMBL16503637 | 0.80 | HSD11B1 (0.30) | HSD11B1 | |
| SCHEMBL29348251 | 0.78 | PER2 (0.35) | PER2CRY2HSD11B1OPRM1OPRD1 | |
| SCHEMBL11607627 | 0.78 | HSD11B1 (0.31) | HSD11B1OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL7395327 | 0.73 | SMN1; SMN2 (0.41) | ALDH1A1 | |
| SCHEMBL29331615 | 0.72 | LIPE (0.33) | ALDH1A1 | |
| SCHEMBL18806202 | 0.72 | HRH3 (0.36) | HSD11B1 | |
| SCHEMBL761946 | 0.71 | GRIN1 (0.42) | PER2CRY2 | |
| SCHEMBL23342003 | 0.71 | ACACB (0.34) | — | |
| SCHEMBL16472303 | 0.71 | MMP1 (0.36) | HSD11B1OPRM1OPRD1OPRK1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170081317-A1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-03-23 | — | — | US | disclosed |
| US-20170081317-A1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170081317-A1 | HETEROARYL COMPOUNDS AS IRAK INHIBITORS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | PER2 4316/4885CRY2 4662/4885HSD11B1 2176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.